A previously treated patient with ≥1% PD-L1-positive cells in tumor might benefit from pembrolizumab as a secondary line therapy, and a previously untreated patient with ≥50% PD-L1-positive cells in tumor might benefit from pembrolizumab as the first-line therapy [26]. This evidence concerns the gene CD274 and neoplasm.